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Abstract Angiogenic switch marks the beginning of
tumor’s strategy to acquire independent blood supply. In
some subtypes of non-Hodgkin’s lymphomas, higher local
vascular endothelial growth factor (VEGF) expression
correlates with increased microvessel density. However,
this local VEGF expression is higher only in tumors with
elevated expression of the receptors of the growth factor,
suggesting an autocrine growth-promoting feedback loop.
Several studies have indicated that VEGF receptors are also
targeted by Tat protein from the HIV-1-infected cells. Given
the similarity of the basic region of Tat to the angiogenic
factors (basic fibroblast growth factor, VEGF), Tat mimics
these proteins and binds to their receptors. We evaluated the
role of HIV-1 Tat in regulating the level of VEGF
expression and microvessel density in the AIDS-related
diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).
By luciferase assay, we showed that VEGF promoter
activity was downregulated in vitro in cells transfected
with Tat. Reduced VEGF protein expression in primary
HIV-1 positive BL and DLBCL, compared to the negative
cases, supported the findings of promoter downregulation
from the cell lines. Microvascular density assessed by
CD34 expression was, however, higher in HIV-1 positive
than in HIV-1 negative tumors. These results suggest that
Tat has a wider angiogenic role, besides the regulation of
VEGF expression. Thus, targeting Tat protein itself and
stabilizing transient silencing of VEGF expression or use of
monoclonal antibodies against their receptors in the AIDS-
associated tumors will open a window for future explorable
pathways in the management of angiogenic phenotypes in
the AIDS-associated non-Hodgkin’s lymphomas.
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Introduction
Under normal circumstances, angiogenesis is restricted to
the sites of vessel injury as well as de novo formation of the
embryonic circulatory system (vasculogenesis). However,
pathological forms of increased angiogenesis have also
been documented for degenerative eye disease, atheroscle-
rosis, and during tumor progression [1].
Angiogenesis is regulated by a plethora of the growth-
and differentiation-promoting factors, which include the
release of angiogenic factors locally by cells under hypoxic
conditions [2–4]. Vascular endothelial growth factor
(VEGF), a dimeric polypeptide growth factor related to
the platelet-derived growth factor, is among the primary
factors modulating the behavior of the endothelial cells in
this process. An increase in VEGF expression in tumors has
been reported in solid and hematological malignancies,
being associated with increased angiogenesis, metastasis,
and poor prognosis [5]. The functions of VEGF are only
effective upon binding to either of the two isoforms of
tyrosine kinase receptors, that is, vascular endothelial
growth factor receptor (VEGFR)-1 (also called fms-like
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In experimental models of AIDS-associated angioproli-
ferative Kaposi’s sarcoma (KS) cells, Tat protein of HIV-1
has been widely implicated in the increased angiogenesis,
and many studies have also indicated that VEGFRs are
targeted by the protein [8]. The basic region of Tat, rich in
arginine and lysine amino acids, is a putative sulfate
heparin-binding domain, which is similar to the sequences
of heparin-binding angiogenic factors (basic fibroblast
growth factor, VEGF) [9]. In particular, it has been
demonstrated that Tat is able to bind to the VEGFR-2/
KDR with high affinity and to determine the activation of
its downstream signaling through its phosphorylation,
similarly to the proper ligand, VEGF [10]. Furthermore,
family of heterodimeric receptors (integrins), which pro-
mote endothelial cells’ adhesion to extracellular compo-
nents and the VEGFR-2/KDR, have been identified as the
two types of signaling receptors activated by extracellular
Tat. Binding of Tat to this receptor has been shown to be
blocked by VEGFR inhibitors, indicating that binding
occurs at the same sites as for the authentic VEGF [11].
Therefore, Tat is characterized as a functional peptide
mimetic for VEGF, a concept that is also tentatively
supported by clinical data [12, 13]. Notwithstanding, studies
on the roles of Tat protein in the oncogenic and angiogenic
phenotypes of non-Hodgkin’s lymphomas are quite limited.
Since the mechanisms by which tumor cells switch to the
angiogenic phenotype involve a balance between angio-
genic stimulators and angiogenic inhibitors, we hypothe-
sized that Tat protein may modulate VEGF expression,
which in turn increases angiogenesis. As B-cells are not a
target for HIV infection, but a soluble form of Tat may be
released from infected cells and taken up by uninfected
ones, in a previous study, we have demonstrated that AIDS-
related lymphomas are positively immunostained with an
anti-Tat antibody [14], thus suggesting that Tat itself may
contribute to an AIDS-related lymphomagenesis.
In the present study, we aimed at investigating whether
Tat may have a role in modulating the activity of the VEGF
promoter, as well as in increasing angiogenic potentials, in
AIDS-related Burkitt lymphomas (BL), and in diffuse large
B-cell lymphomas (DLBCL).
Materials and methods
Study cases
A total of twenty-nine, 10% formalin-fixed paraffin-
embedded tissue blocks of DLBCL and BL were retrieved
at random from the archives of the Department of Human
Pathology and Oncology, University of Siena, Italy and the
Department of Pathology of the Aga Khan Hospital, Kenya.
Informed consent to carry out the study was granted by the
institutions’ ethical review committee and it was in accor-
dance with the declaration of Helsinki. Sections made from
these paraffin embedded tissue blocks were stained with
hematoxylin and eosin to confirm the previous diagnoses.
Sections made from the tissue blocks were stained with
hematoxylin/eosin and immunophenotyping done to con-
firm the previous diagnoses. HIV-1 status was confirmed by
the polymerase chain reaction (PCR) analyses, and the
study cases were then classified as shown in Table 1. The
presence of Epstein–Barr virus (EBV) was assessed by in
situ hybridization for EBV-encoded RNA (EBER) using a
30-base oligonucleotide probe complementary to a portion
of the EBV-encoded small nuclear RNA (EBER1) gene, as
previously described [14].
Cell lines
The human 293 cell line and the Burkitt lymphoma-derived
cell line Raji were obtained from the American Type Culture
Collection (Rockville, MD, USA). Two hundred ninety-
three cells were cultured in Dulbecco’s modified eagle’s
medium supplemented with 10% fetal bovine serum (FBS),
1% L-glutamine, and 1% penicillin/streptomycin, in a
humidified atmosphere containing 5% CO2, at 37°C. Raji
cells were grown in RPMI medium supplemented with 10%
FBS, 1% L-glutamine, and 1% penicillin/streptomycin, in a
humidified atmosphere containing 5% CO2, at 37°C.
Plasmids
Both the artificial VEGFR promoter, linked to a luciferase
reporter gene, and the pcDNA3-Tat vector have been
previously described [15].
Transfections
The 293 cells represent a useful model, resulting in high
transfection efficiencies, to achieve ectopic expressions of
targeted gene. The in vitro experiments using VEGF
promoter were therefore performed in the 293 cells and then
confirmed in the Raji cells. The 293 cells were transfected
with the calcium phosphate kit (Invitrogen, CA, USA),
whereas the Raji cells were transfected by the nucleofection
using an AMAXA apparatus, with solution T and program
T16 (Amaxa, Germany). Forty-eight hours after the trans-
fections, cells were harvested for luciferase assay.
Luciferase assay
For luciferase assay, two micrograms of each plasmid
were transfected. Cells were harvested 48 h from the
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assay was performed in triplicate, as previously described
[16]. Luciferase activity was assayed using a dual
luciferase assay kit according to the manufacturer’s
instructions (Promega, Madison, WI, USA) and measured
using a luminometer (Turner, Promega, Madison, WI,
USA).
Immunohistochemical staining
Immunohistochemistry was performed on sections from
primary tumors by the immunoperoxidase (for CD34) and
alkaline–anti-alkaline phosphatase (for VEGF) techniques,
following preheat retrieval of antigen epitopes. The
technique of immunohistochemistry has been previously
described [17]. The clones of monoclonal antibodies and
concentrations used are shown in Table 2. Unlike anti-
CD31, the antibody CD34 does not cross-react with
lymphoid cells, and better quality of staining than with
anti-factor VIII was obtained.
Evaluation of immunostaining
VEGF and CD34 staining were initially graded on a scale
of 0 to 3, depending on the intensity of the staining as
described in Table 3. This grading scale is a modification of
the Takahashi et al. system [18].
Microvessel count and density
Microvessel density (MVD) was evaluated as previously
described [19]. Briefly, CD34 stained sections underwent
individual microvessel count on a grid square of
0.025 mm
2, at ×630 magnification in the 11 identified
areas of most intense immunostains using Zeiss Axioscop
40 microscope (Carl Zeiss, Germany). MVD was defined
as the mean number of microvascular profiles per mm
2
from the 11 hot spots assessed in each study case. Any
brown-staining endothelial cell or endothelial cell cluster
clearly separated from adjacent microvessels, tumor cells,
and normal cells with or without the presence of a lumen
was considered as a single countable microvessel. The
average of microvessel counts from the 11 hot spots for
each case was used for MVD assessment. Immunostains
and the vessel counts were assessed without prior
knowledge of the patients’ HIV-1 status by two patholo-
gists independently, obtaining concordance of more than
98%. Where discordance was noted, the two pathologists
reviewed the cases simultaneously using double-headed
light microscope.
HIV-1 testing using PCR technique
For HIV-1 testing, DNA was extracted and nested PCR
performed as previously described [20].
Statistical analyses
Differences in mean vessel counts, mean staining, and
intensity of VEGF among HIV-1 positive and HIV-1
negative cases were analyzed by the SYSTAT statistical
program. Kruskal–Wallis one-way analysis was used to test
the association between microvessel counts and HIV-1
status. Pearson correlation matrix was then used to test
interparametric correlations, and values of p<0.05 were
considered statistically significant.
Results
HIV-1 Tat downregulates VEGF promoter activity
We aimed at investigating whether Tat was able to
modulate the activity of the VEGF promoter. Therefore,
Table 2 Clones of antibodies used and their source
Antibody Clone (dilutions) Source
VEGF VG1 (1:100) DAKO (Milan, Italy)
CD34 QBEnd 10 (1:100) DAKO (Milan, Italy)
Table 3 Immunoassay score used for both VEGF and CD34
Score % positive cells Intensity of the reaction
0 No positive cells No positive reaction
1 <10% positive cells Faint color reaction
21 0 –50% positive cells Moderate color reaction
3 >50% positive cells Intense color reaction
Table 1 Classification of study cases
Lymphoma type
(number)
Age range
(median)
Sex
(female/male)
Site
(nodal/extranodal)
EBV+/total HIV+/total
BL (16) 4/56 (17) 4/12 6/10 14/16 6/16
DLBCL (13) 27/45 (36) 3/10 6/7 6/13 8/13
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alone or in combination with a vector coding for Tat, was
transfected in 293 and Raji cells. Luciferase assay showed
that Tat protein is able to downregulate the activity of the
VEGF promoter, as compared with the empty vector-
transfected cells (Fig. 1a and b). The repression of VEGF
promoter due to Tat binding was correlated with the low
expression of VEGF in HIV-1 positive primary tumors
compared to the negative cases (Fig. 2).
HIV-1 positive DLBCL and BL have different patterns
of microvessel density from the negative cases
It is known that Tat is released in a soluble form by the
infected cells and taken up by the uninfected ones [21]. In
fact, a previous study of our group showed that AIDS-
associated B-cell lymphomas were positive when immu-
nostained with an anti-Tat antibody, thus indicating that
Tat may act as an oncogenic factor [14]. In the present
study, we tested primary tumor cases for the expressions of
VEGF and CD34 (a specific marker for microvessel
density), and a distinct pattern between the HIV-1 positive
and HIV-1 negative cases was observed. In the AIDS-
associated cases, low expression of VEGF, consistent with
inactivated VEGF expression, was realized in both BL and
DLBCL (Fig. 2). These findings were consistent with those
obtained from the cell lines, in which VEGF promoter
repression resulted in reduced luciferase activity. Evaluated
through CD34 expression, increased MVD in HIV-1
positive tumors was observed (Fig. 3), pointing to the role
that Tat plays in the increased endothelial cell proliferation
and augmented vasculature. In HIV-1 positive DLBCL,
statistical significant values for microvessel counts, as well
as the mean number of microvessels, were realized for the
minimum counts (p=0.010), maximum counts (p=0.003),
median number of counts (p=0.005), and mean (p=0.003).
In HIV-1 positive BL cases, minimum microvessel counts
(p=0.042), maximum counts (p=0.048), and median (p=
0.034) reached the statistical significant values, with a
borderline figure for the mean (p=0.051; Fig. 4). This
could be attributed to the other angiogenic factors as have
been previously reported [22]. EBV status did not influence
microvessel formation.
Discussion
Differences in VEGF expression and correspondingly
higher microvessel density among the subtypes of non-
Hodgkin’s lymphomas have been suggested to have
important implications for the responsiveness of these
tumors to the anti-angiogenic therapies. Both experimental
and clinical data related to angiogenesis in the hema-
poietic neoplasia are relatively limited. However, an
increase in the expression of angiogenic factors and
microvessel density has been linked to increase angiogen-
esis, tumor progression, and poor prognosis in both solid
and hematological malignancies [22].
Tumors are known to stimulate local vascular endothelial
growth factor expression and autocrine growth-promoting
feedback loop during pathological angiogenesis. Besides,
all members of the VEGF family stimulate endothelial
cellular responses by binding to tyrosine kinase recep-
tors (VEGFRs) on the cell surface, causing them to
dimerize and become activated through transphosphory-
lation, although to the different sites and extents [23,
24]. Vascular endothelial growth factor, an important
endothelial cell mitogen associated with increased an-
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Fig. 1 Luciferase assay for VEGF promoter activity in both Tat- and
empty vector-transfected 293 cell line (a) and Raji cell line (b).
Ectopic expression of Tat in 293 cells is able to downregulate the
activity of a VEGF promoter linked to a luciferase reporter gene (a).
These findings were confirmed in the Tat-transfected Raji cells (b)
6 J Hematopathol (2008) 1:3–10giogenesis and aggressive tumor is well-characterized in
the AIDS-associated angioproliferative tumor, KS. Its
stimulating effect on endothelial cells is, however, still
largely dependent on the presence of specific VEGF
receptors, such as the VEGFR2 (Flk-1/KDR) receptor
[25–29].
Previous studies have shown that Tat protein released by
the infected cells in HIV-1 positive patients is a potential
angiogenic factor and contributes to increase angiogenesis
through binding to VEGFR-2 (Flk-1/KDR). Based on these
facts, we analyzed the possibility that Tat may cooperate
with VEGF in inducing angiogenesis. Our findings dem-
Fig. 2 VEGF expression in pri-
mary HIV-1 positive or negative
DLBCL and BL tumors. Higher
expression of VEGF was ob-
served for HIV-1 negative
DLBCL (a) and BL (c), as
compared to the corresponding
histotypes in HIV-1 negative
cases (b and d), respectively
Fig. 3 CD34 expression in both
DLBCL and BL positive or
negative for HIV-1. Irrespective
of the histotype, expression of
CD34 was low in HIV-1 nega-
tive DLBCL (a) and BL (c), as
compared to the corresponding
histotypes positive for HIV-1 (b
and d), respectively
J Hematopathol (2008) 1:3–10 7onstrated that Tat diminishes the promoter activity of VEGF
promoter in vitro, suggesting that Tat may modulate the
level of expression of VEGF. In the studied primary HIV-1
positive or HIV-1 negative diffuse large B-cell and Burkitt
lymphomas, low expression of VEGF in HIV-1 positive as
compared to the negative cases was observed, confirming
the in vitro results. However, the microvessel density,
assessed by CD34 expression, was intriguing being higher
in HIV-1 positive as compared to the negative cases. This
suggests that Tat plays a wider angiogenic role that is
related to increase MVD. From our findings, it is possible
to argue that Tat may increase angiogenesis through the
direct binding to VEGFR2/KDR, thus inducing its down-
stream signaling rather than increasing angiogenesis
through the enhancement of VEGF expression [30]. This
may well explain why VEGF expression did not correlate
with CD34 expression in the AIDS-related samples.
It has been demonstrated that endothelial cells express
high levels of VEGFR1 (Flt-1) [31], a VEGF receptor with
a higher affinity for VEGF as compared to KDR [32].
Although it has a higher affinity for VEGF, Flt-1 appears to
be principally involved in the endothelial cell differentia-
tion rather than in the vessel formation [33]. Through its
higher affinity, Flt-1 could sequester partly or mostly of the
VEGF produced. These observations suggest that the
endogenous ligand for this receptor, VEGF, appears to be
present at limiting the concentrations in vivo, whereas an
exogenous ligand, such as Tat, would be free to bind and
activate KDR. This, in part, could underlie the low VEGF
expression in AIDS-associated lymphomas observed in our
study cases. Other contributing angiogenic factors have,
however, been elsewhere reported [34–36]. These results
were not surprising given that HIV-1 Tat, which affects
endothelial functions, has also been shown to downregulate
endothelial differentiation-related factor-1, a novel gene
product which could be downregulated when endothelial
cells are induced to differentiate in vitro both at the RNA
and protein levels [37].
While some studies reported no correlation between
microvessel density and tumor grade [38, 39], the
findings of this study suggest the need to design therapies
targeting VEGF, VEGFRs, as well as Tat in the manage-
ment approach in angiogenic phenotypes of AIDS-
associated non-Hodgkin’s lymphomas. Furthermore, it
may be more interesting to dissect the molecular
mechanisms underlying the activity of VEGF mimetic
by Tat, given the functional interaction of receptors with
dimeric ligand, molecules are known to dimerize recep-
tors, followed by the activation of the intracellular kinase
domain, of which no evidence so far has shown that Tat
basic peptide is characterized [40, 41].
Although a much smaller binding epitope on the VEGF
receptor surface is expected to be covered by the low-
monomeric (low-Mr) Tat peptide mimetic of VEGF as
Fig. 4 Microvessel counts and
mean in both HIV-1 positive and
HIV-1 negative BL and DLBCL
tumors. In both BL and
DLBCL, statistical significant
values for microvessel counts
were realized for the minimum
(a; p=0.042 and p=0.010),
maximum (b; p=0.048 and p=
0.003), and median (c; p=0.034
and p=0.005), respectively. The
mean for DLBCL was statisti-
cally significant but that of BL
was on the borderline (d; p=
0.003 and p=0.051) being at-
tributed to the other angiogenic
factors
8 J Hematopathol (2008) 1:3–10compared to the highly complex dimeric VEGF, this study
reveals that Tat mimetic of VEGF correlates well with the
increased microvessel density. Therefore, future therapeutic
designs targeting VEGF, VEGFRs, as well as Tat protein in
the management of angioproliferative phenotypes of AIDS-
associated non-Hodgkin’s lymphomas may increase the
chances of obtaining optimal therapy.
Acknowledgements This work was supported by an MIUR grant,
Rome, Italy (L.L); MPS Foundation grant, Siena, Italy (L.L); and PAR
grant, University of Siena, Siena-Italy (L.L).
References
1. Scheidegger P, Weiglhofer W, Suarez S, Console S, Waltenberger J,
Pepper MS,Jaussi R,Ballmer-HoferK(2001)Signalling properties
of an HIV-encoded angiogenic peptide mimicking vascular
endothelial growth factor activity. Biochem J 353:569–578
2. Bergers G, Benjamina LE (2003) Tumorigenesis and angiogenic
switch. Nat Rev Cancer 3:401–410
3. Rosen LS (2002) Clinical experience with angiogenesis signalling
inhibitors: focus on vascular endothelial growth factor (VEGF)
blockers. Cancer Control 9(Suppl 2):36–44
4. McMahon G (2005) VEGF receptor signalling in tumour
angiogenesis. Oncologist 5(Suppl 1):3–10
5. Dvorak HF (2002) Vascular permeability factor/vascular endothe-
lial growth factor: a critical cytokine in tumour angiogenesis and
potential target for diagnosis and therapy. J Clin Oncol 20:4368–
4380
6. Warner-Schmidt JL, Duman RS (2007) VEGF is an essential
mediator of the neurogenic and behavioural actions of antide-
pressants. Proc Natl Acad Sci U S A 104(11):4647–4652
7. Brkovic A, Sirois MG (2007) Vascular permeability induced by
VEGF family members in vivo: role of endogenous PAF and NO
synthesis. J Cell Biochem 100(3):727–737
8. Dezube BJ (2000) New therapies for the treatment of AIDS-
related Kaposi sarcoma. Curr Opin Oncol 12(5):445–449
9. Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A,
Paglialunga G, Bussolino F, Noonan D (1996) HIV-1 Tat protein
is a heparin-binding angiogenic growth factor. Oncogene 12:289–
297
10. Morini M, Benelli R, Giunciuglio D, Carlone S, Arena G,
Noonan DM, Albini A (2000) Kaposi’s sarcoma cells of
different etiologic origins respond to HIV-Tat through the Flk-
1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem
Biophys Res Commun 273:267–271
11. Rusnati M, Presta M (2002) HIV-1 Tat protein and endothelium:
from protein/cell interaction to AIDS-associated pathologies.
Angiogenesis 5:141–151
12. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S,
Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC (1994)
Synergy between basic fibroblast growth factor and HIV-1 Tat
protein in induction of Kaposi’s sarcoma. Nature (London)
371:674–680
13. Gallo RC (1996) The enigmas of Kaposi’s sarcoma. Science
282:1837–1839
14. Lazzi S, Bellan C, De Falco G, Cinti C, Ferrari F, Nyongo A,
Claudio PP, Tosi GM, Vatti R, Gloghini A, Carbone A,
Giordano A, Leoncini L, Tosi P (2002) Expression of RB2/
p130 tumor-suppressor gene in AIDS-related non-Hodgkin’s
lymphomas: implications for disease pathogenesis. Human
Pathol 33:723–731
15. ClaudioPP,StieglerP,HowardCM,BellanC,MinimoC,TosiGM,
Rak J, Kovatich A, De Fazio P, Micheli P, Caputi M, Leoncini L,
Kerbel R, Giordano A (2001) RB2/p130 gene enhanced expres-
sion down-regulates vascular endothelial growth factor expression
and inhibits angiogenesis. Cancer Res 61:462–468
16. De Falco G, Bagella L, Claudio PP, De Luca A, Fu Y, Calabretta
B, Sala A, Giordano A (2000) Physical interaction between CDK9
and B-Myb results in suppression of B-Myb gene autoregulation.
Oncogene 19:373–379
17. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK (2001) Micro
vessel density, vascular endothelial growth factor and its receptors
Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin
Pathol 116(6):838–845
18. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM
(1995) Expression of vascular endothelial growth factor and
its receptor, KDR, correlates with vascularity, metastasis, and
proliferation of human colon cancer. Cancer Res 55:3964–
3968
19. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell
cycle: a review of regulation, deregulation and therapeutic targets
in cancer. Cell Prolif 36:131–149
20. Gala JL, Vandenbroucke AT, Vandercam B, Pirnay JP, Delferrière
N, Burtonboy G (1997) HIV-1 detection by nested PCR and viral
culture in fresh or cryopreserved post-mortem skin: potential
implications for skin handling and allografting. J Clin Pathol 50
(6):481–484
21. Barillari G, Ensoli B (2002) Angiogenic effects of extra cellular
human immunodeficiency virus type 1 Tat protein and its role in
the pathogenesis of AIDS-associated Kaposi’s sarcoma. Clin
Microbiol Rev 15:310–326
22. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ,
Hammer AS, Hamilton-Dutoit S, Natkunam Y (2007) Micro
vessel density and expression of vascular endothelial growth
factor and its receptors in diffuse large B-cell lymphoma subtypes.
Am J Pathol 170(4):1362–1369
23. Reigstad LJ, Varhaug JE, Lillehaug JR (2005) Structural and
functional specificities of PDGF-C and PDGF-D, the novel
members of the platelet-derived growth factors family. FEBS J
272(22):5723–5741
24. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K
(2007) Structure of a VEGF–VEGF receptor complex determined
by electron microscopy. Nat Struct Mol Biol 14(3):249–250
25. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, Dias
S (2007) VEGF and VEGFR-2 (KDR) internalization is required
for endothelial recovery during wound healing. Exp Cell Res 313
(8):1561–1574
26. Yamazaki Y, Nakano Y, Imamura T, Morita T (2007)
Augmentation of vascular permeability of VEGF is enhanced
by KDR-binding proteins. Biochem Biophys Res Commun 355
(3):693–699
27. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF,
Veale DJ (2003) Angiopoietins, growth factors, and vascular
morphology in early arthritis. J Rheumatol 30(2):260–268
28. Waltenberger J (1997) Modulation of growth factor action:
implications for the treatment of cardiovascular diseases.
Circulation 96(11):4083–4094
29. Aoki Y, Tosato G (2003) Targeted inhibition of angiogenic factors
in AIDS-related disorders. Curr Drug Targets Infect Disord 3
(2):115–128
30. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L,
Noonan D, Salio M, Camussi G, Rockl W, Bussolino F (1996)
The angiogenesis induced by HIV-1 tat protein is mediated by the
Flk-1/KDR receptor on vascular endothelial cells. Nat Med 2
(12):1371–1375
31. Brown LF, Tognazzi K, Dvorak HF, Harrist TJ (1996) Strong
expression of kinase insert domain-containing receptor, a vascular
J Hematopathol (2008) 1:3–10 9permeability factor/vascular endothelial growth factor receptor in
AIDS-associated Kaposi’s sarcoma and cutaneous angiosarcoma.
Am J Pathol 148:1065–1074
32. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van De Water L,
Senger DR (1995) Vascular permeability factor/vascular endothe-
lial growth factor: an important mediator of angiogenesis in
malignancy and inflammation. Int Arch Allergy Immunol
107:233–235
33. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role
of the Flt-1 receptor tyrosine kinase in regulating the assembly of
vascular endothelium. Nature 376:66–70
34. Bardelli M, Leucci E, Schurfeld K, Bellan C, Passiatore G,
Rocchigiani M, Bartolommei S, Orlandini M, Zagursky J,
Lazzi S, De Falco G, Tosi P, Oliviero S, Leoncini L (2007)
VEGF-D is expressed in activated lymphoid cells and in tumors of
hematopoietic and lymphoid tissues. Leuk Lymphoma 48
(10):2014–2021
35. Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A,
Rigby H, Harper SJ, Bates DO (2007) Expression of VEGF (xxx)
b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J
Cancer 97(2):223–230
36. Petersen W, Pufe T, Unterhauser F, Zantop T, Mentlein R, Weiler
A (2003) The splice variants 120 and 164 of the angiogenic
peptide vascular endothelial cell growth factor (VEGF) are
expressed during Achilles tendon healing. Arch Orthop Trauma
Surg 123(9):475–480
37. Dragoni I, Mariotti M, Consalez GG, Soria MR, Maier JA
(1998) EDF-1, a novel gene product down-regulated in human
endothelial cell differentiation. J Biol Chem 273(47):31119–
31124
38. Mazur G, Wróbel T, Dziegiel P, Jeleń M, Kuliczkowski K, Zabel
M (2004) Angiogenesis measured by expression of CD34 antigen
in lymph nodes of patients with non-Hodgkin’s lymphoma. Folia
Histochem Cytobiol 42(4):241–243
39. Zagury D, Lachgar A, Chams V et al (1998) Interferon alpha and
Tat involvement in the immunosupression of uninfected T cells
and C–C chemokine decline in AIDS. Proc Natl Acad Sci U S A
95:3851–3856
40. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P,
Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a
target of bevacizumab in cancer: from the biology to the clinic.
Curr Med Chem 13(16):1845–1857
41. Dell’Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A,
Efferth T (2004) Inhibition of angiogenesis in vivo and growth of
Kaposi’s sarcoma xenograft tumors by the anti-malarial artesu-
nate. Biochem Pharmacol 68(12):2359–2366
10 J Hematopathol (2008) 1:3–10